Agreement and Trading Update

Dechra Pharmaceuticals PLC
28 November 2007

Issued by Citigate Dewe Rogerson Ltd, Birmingham
Date: Wednesday, 28 November 2007
                                                               Embargoed: 7.00am


            Dechra(R) Pharmaceuticals PLC ('Dechra' or the 'Group')

                US Operation Dechra Veterinary Products ('DVP')
           Secures Exclusive Marketing and Distribution Rights for IRAP(TM)
                                      and
                                 Trading Update

Exclusive Marketing and Distribution Rights for IRAP(TM) for US

DVP has secured an exclusive agreement with Orthogen Veterinary GmbH 
('Orthogen') to market and distribute the patented IRAP(TM) therapy system in 
the US veterinary market. IRAP therapy utilises the animal's own blood and 
natural healing mechanisms and is a recent innovation in the treatment of equine
osteoarthritis.

The patented IRAP syringe produces autologous conditioned serum ('ACS'), which
contains active quantities of anti-inflammatory and regenerative cytokines.  The
therapy has been used to treat a variety of lameness issues and has proven
efficacious in multiple clinical trials in horses around the world.

Current annualised revenues in the US for the IRAP therapy are approximately
US$1.2 million. DVP is committed to investing in specialised, efficacious,
value-added products to serve the equine and small animal markets and we believe
that the IRAP therapy is a strong addition to the Group's US product portfolio.

The Directors believe that its DVP US team has the skills and expertise to
increase the awareness and benefits of IRAP therapy in the US veterinary market
as well as enhancing revenues in the future.

Product Update

Vetoryl(R) US

As shareholders are already aware the Group has been notified by the FDA that it
considers the Safety section for Vetoryl Capsules to be approved. Subsequently,
the Efficacy section has been submitted to the FDA for review.

The Directors are focused on obtaining full US marketing authorisation for
Vetoryl Capsules and remain confident that this will be achieved before the end
of 2008 calendar year.

EU approval for Ovuplant(R)

Dechra Veterinary Products EU ('DVP EU') has received EU marketing approval to
market and distribute Ovuplant in Europe. The initial launch by DVP EU will be
focused on the main equine territories of Central Europe (Eire, France, Germany,
Italy, Holland and Spain) and commence in January 2008.

Generics under Development

DVP EU has three EU generics which are at an advanced stage of development, one
of which is expected to be launched into the canine market in a number of
European countries during Spring 2008.

Trading Update

Trading around the Group continues to be very encouraging and the financial
position of the Group remains strong with trading in-line with management
expectations.

The Services Division continues to take advantage of strong market conditions in
the UK and, the Pharmaceuticals Division has made further excellent progress
both in the UK and in international markets.

The Group's US pharmaceuticals business, DVP is already achieving solid revenues
from the Pharmaderm products acquired in May and trading profitably.

The Group's Interim Results for the period ending December 2007 are scheduled to
be announced at the end of February 2008.

Enquiries:
Ian Page, Chief Executive                                 Fiona Tooley, Director
Simon Evans, Group Finance Director                       Keith Gabriel, Senior Account Manager
Dechra Pharmaceuticals PLC                                Citigate Dewe Rogerson
Tel: [phone]                                  Tel:[phone]
Mobile:[phone] (IP)                           Mobile: [phone] (FMT)
www.dechra.com
[e-mail]



Editors Notes:

Dechra Pharmaceuticals PLC (LSE Ticker: DPH)

Dechra operates under two divisions; Pharmaceuticals and Services. Both
divisions are focused on the veterinary market with a key area of specialisation
being on companion animal products.  The Group employs over 750 people across
its 17 locations in the UK and USA. www.dechra.com

Trade Marks appear throughout this release in italics.  Dechra and the Dechra '
D' logo are registered Trade Marks of Dechra Pharmaceuticals PLC.


                      This information is provided by RNS
            The company news service from the London Stock Exchange